Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MIRA Pharmaceuticals, Inc. ( (MIRA) ) has provided an announcement.
On July 29, 2025, MIRA Pharmaceuticals announced promising preclinical results for its new topical Ketamir-2 formulation, which showed comparable efficacy to injected morphine in reducing pain behaviors in a rodent model. The study highlights Ketamir-2’s potential as a non-opioid treatment for localized pain conditions, supporting its continued development and clinical trials.
The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing non-opioid treatments for pain management. The company’s primary products include formulations like Ketamir-2, aimed at addressing both acute and chronic pain conditions.
Average Trading Volume: 1,487,045
Technical Sentiment Signal: Strong Buy
For a thorough assessment of MIRA stock, go to TipRanks’ Stock Analysis page.